Intrinsic Medicine, Inc. (INRX)

Intrinsic Medicine was planning to go public, but the IPO has been withdrawn.
IPO Price Range
$5.00 - $7.00
Shares Offered
Deal Size
Chart not available yet
Data will show when the stock starts trading.
Market Cap 67.74M
Revenue (ttm) n/a
Net Income (ttm) -11.95M
Shares Out 11.29M
EPS (ttm) -1.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open n/a
Previous Close n/a
Day's Range n/a
52-Week Range n/a
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About INRX

Intrinsic Medicine is a preclinical-stage therapeutics company leveraging synthetic biology-manufactured human identical milk oligosaccharide, or HiMO, molecules as new medicines to treat large patient populations underserved by current treatment options. In the first half of 2023, we plan to initiate a Phase 2 clinical trial under an approved protocol in Australia to test our lead drug candidate in over 400 patients with the constipation dominant form of irritable bowel syndrome, or IBS-C, which is estimated to affect approximately five millio... [Read more]

Industry Health Care
Sector Pharmaceuticals
Founded 2018
Employees 8
Stock Exchange NASDAQ
Ticker Symbol INRX
Full Company Profile

Financial Performance

Financial Statements


Inflammatory disease biotech Intrinsic Medicine files for a $29 million IPO

Intrinsic Medicine, a preclinical biotech developing HiMO therapies for GBA and inflammatory disorders, filed on Friday with the SEC to raise up to $29 million in an initial public offering.

1 year ago - Renaissance Capital

Intrinsic Medicine IPO Registration Document (S-1)

Intrinsic Medicine has filed to go public with an IPO on the NASDAQ.

1 year ago - SEC